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Zhigang Zhang1†, Chao Ni1†, Wuzhen Chen1, Ping Wu1, Zhen Wang1, Junhua Yin1, Jian Huang1,2* and Fuming Qiu2*Abstract
Background: The chemokine receptor CXCR4 plays a significant role in biological processes, as well as in
tumorigenesis and the progression of cancer, especially breast cancer. However, the clinical application of CXCR4
for breast cancer prognosis is still very limited. A meta-analysis based on published studies was performed with the aim
of obtaining an accurate evaluation of the relationship between CXCR4 expression and the prognosis of breast cancer.
Methods: A comprehensive search strategy was used to search relevant literature in PubMed, MEDLINE and the ISI Web
of Science. The correlation between CXCR4 expression and clinicopathological features and breast cancer prognosis was
analyzed. This meta-analysis was carried out using Review Manager 4.2.
Result: Thirteen eligible studies consisting of 3865 participants were included. We found that breast cancers with CXCR4
expression were associated with lymph node status (pooled RR =1.20, 95% CI: 1.01-1.43, P<0.001) and distant metastasis
(pooled RR =1.52, 95% CI: 1.17-1.98, P = 0.125). CXCR4 overexpression was significantly associated with disease free
survival (DFS) (RR = 0.77, 95% CI = 0.70–0.86, P = 0.554) and overall survival (OS) (RR = 0.70, 95% CI = 0.59–0.83, P = 0.329).
However, there was no significant association between CXCR4 expression and some clinical parameters of breast cancer,
such as tumor category, ER status, PR status, or c-erbB-2 status.
Conclusion: Our meta-analysis showed that CXCR4 is an efficient prognostic factor for breast cancer. Overexpression of
CXCR4 was significantly associated with lymph node status and distant metastasis and indicated poor overall and disease
free survival.
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Breast cancer is the most common form of cancer diag-
nosed in women. Thus far in 2013, breast cancer has ac-
counted for 29% of all new cancer cases and 14% of all
cancer deaths among women worldwide [1]. Breast cancer-
related mortality is associated with the development of
metastatic potential of the primary tumor. Recently, many
studies have shown that the presence of CXCR4 can signify
invasion and metastasis in several cancers, including breast
cancer [2].
The chemokine receptor CXCR4 is a 352-amino acid
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stated.selectively binds the CXC chemokine stromal cell-derived
factor 1 (SDF-1), also known as CXCL12. This chemokine
receptor has been identified to play a crucial role in a
number of biological processes, such as trafficking and
homeostasis of immune cells such as T lymphocytes [3],
and the CXCL12/CXCR4 axis is known to be important in
the enhancement of stem cell homing in tissue regener-
ation [4]. In various types of cancer, CXCR4 plays a vital
role in tumorigenesis and the progression of cancer [5,6].
A potential mechanism of CXCR4’s involvement in tumor
dissemination and metastasis is through promoting its
transendothelial migration at the primary site [7]. Further
evidence indicates that CXCR4 not only affects breast can-
cer metastasis but also promotes the survival and prolifer-
ation of breast cancer cells through increasing the number
of blood vessels in tumors [8]. However, there are insuffi-
cient studies to confirm the clinical significance of CXCR4
in breast cancer, and its accurate prognostic value inLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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lecular types of breast cancer. To address this issue, we
conducted a meta-analysis aimed at evaluating the value
of CXCR4 as a prognostic marker for breast cancer and to
determine the relationship between CXCR4 and several
clinicopathological features of breast cancer.
Methods
Publication search
This systematic review and meta-analysis is reported ac-
cording to the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) statement [9]. The
electronic databases PubMed (http://www.ncbi.nlm.nih.
gov/pubmed/), MEDLINE and ISI Web of Science were
searched using the following tags: “CXCR4” and “breast
cancer”. The citation lists associated with the studies, in-
cluding review articles, that were retrieved in the search
were used to identify additional relevant publications. The
articles utilized in this study were published up to March
2013. The title and abstract of each study identified in the
search were scanned to exclude any clearly irrelevant
reports.
Selection criteria
The studies included in this meta-analysis were either
randomized controlled studies (RCTs) or observational
studies (case–control or cohort) that evaluated the associ-
ation between CXCR4 expression and breast cancer. The
criteria for inclusion were as follows: a) articles evaluating
the relationship between CXCR4 expression and parame-
ters such as clinicopathological features and prognostic
factors of breast cancer; b) articles containing sufficient
published data to determine an estimate of relative risk
(RR) and a 95% confidence interval (95% CI); and c) full
text, original research articles published in English.
Letters to the editor, reviews, comments, duplicated
studies and articles published in books as well as papers
published in non-English languages were excluded.
Data extraction
All data were independently abstracted by two reviewers
with standardized data abstraction tools. Disagreements
in data extraction were resolved by consensus and by re-
ferring back to the original article. The following data
were obtained from each article: first author’s last name;
year of publication; country of the population studied; num-
ber of participants; duration of follow-up; staining methods
of CXCR4; staining patterns of CXCR4; the choice of cutoff
scores for the definition of positive staining or staining
intensity; T category (T0-2, T3-4); N category; distant me-
tastasis; c-erbB-2, ER and PR status; and most importantly,
the 5-year overall survival (OS) and disease-free survival
(DFS) rates.Because the cutoff value for the CXCR4 group varied
among studies, we defined CXCR4-high expression values
according to the original articles. The T category was de-
termined according to the American Joint Committee on
Cancer (AJCC) cancer staging manual (one group: T0-2,
other group: T3-4). To avoid bias from studies contributing
very long-term follow-up data compared with other stud-
ies, both OS and DFS were standardized to include 5 years
of follow-up in all studies. For the articles that did not pro-
vide 5-year OS and DFS rates directly, Kaplan–Meier
curves were evaluated using GetData Graph Digitizer 2.24
(http://getdatagraph-digitizer.com).
Statistical analysis
Statistical analyses were performed according to the guide-
lines proposed by the Meta-Analysis of Observational Stud-
ies in Epidemiology group. The relative risk (RR) with 95%
confidence interval (95% CI) was calculated using Review
Manager 4.2. Study heterogeneity was measured using the
Q test and I2 test. Fixed-effects models (Mantel-Haenszel,
P>0.1 and I2<50%) assume that the differences between the
results of various studies are due to chance. Random-
effects models (DerSimonian and Laird, P ≤ 0.1 or I2 ≥ 50%)
assume that the results could genuinely differ between
studies. In the absence of heterogeneity, both fixed- and
random-effects models provide similar results. When het-
erogeneity is present, the random-effects model is consid-
ered to be more appropriate than a fixed-effects model,
resulting in wider intervals and a more conservative esti-
mate of treatment effect. The potential for publication bias
was assessed using the Begg rank correlation method and
the Egger weighted regression method (software Stata 11.0,
P<0.05 was considered representative of statistically signifi-
cant publication bias). All P values are two tailed.
Results
Search results
The detailed search steps are described in Figure 1. Initially,
288 articles were retrieved utilizing the search strategy de-
scribed above. After titles and abstracts were reviewed, 260
articles were excluded due to the end point of the study;
some studies did not provide data between CXCR4 expres-
sion and pathological features or specify whether disease
free survival (DFS)/overall survival (OS) was investigated.
Of the published articles, 15 studies were excluded because
they were about CXCR4 mRNA, CXCR4 shRNA, CXCR4
gene expression or the CXCR4 signaling pathway. Finally, a
total of 13 studies were included in the meta-analysis.
Characteristics of eligible studies
All features of the 13 eligible studies are listed in Table 1.
These thirteen observational retrospective studies, con-
sisting of approximately 3865 participants with a median
of 297 (from 54 to 1699) per study, were included. These
Figure 1 Flowchart of the selection of studies for inclusion in
the meta-analysis.
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ation parameters for breast cancer, based on either clini-
copathological features or prognostic factors. Among
them, 7 were from the USA, 1 was from Canada, 3 were
from China, 1 was from Japan, and 1 was from Korea.
We did not obtain any studies from Europe. In addition,
the expression of CXCR4 was detected by immunohisto-
chemistry (IHC) in 3 studies, by tissue microarray
(TMA) in 2 studies and by western blot analysis in 6
studies.Correlation of CXCR4 expression with clinicopathological
parameters
CXCR4 expression was not associated with certain clin-
ical parameters of breast cancer, such as tumor category
(T category: T0-2, T3-4) (pooled RR =1.09, 95% CI: 0.80-
1.47, P = 0.451 and I2 = 0 fixed-effect), ER status (pooled
RR =0.97, 95% CI: 0.97-1.05, P = 0.014 and I2 = 51.3
random-effect), PR status (pooled RR =0.99, 95% CI: 0.87-
1.12, P = 0.016 and I2 = 51.5 random-effect), or c-erbB-2
status (pooled RR =1.16, 95% CI: 0.85-1.56, P<0.001 and
I2 = 84.9 random-effect) (Figure 2a,d,e,f).
However, breast cancers with CXCR4 expression were
associated with lymph node status (pooled RR =1.20,
95% CI: 1.01-1.43, P<0.001 and I2 = 80.9 random-effect)
and distant metastasis (pooled RR =1.52, 95% CI: 1.17-
1.98, P = 0.125 and I2 = 42.1 random-effect) (Figure 2b,c).
In the staining pattern subgroup analysis, CXCR4 mem-
brane and/or cytoplasm expression (pooled RR =1.72, 95%
CI: 1.29-2.29, P = 0.121 and I2 = 48.4 random-effect) had a
more significant association with distant metastasis than
nuclear CXCR4 expression. Additional results from the
subgroup analyses can be found in Additional file 1: Tables
S1 and Additional file 2: Tables S2.Impact of CXCR4 expression on 5-year OS and DFS rates
The relationship between CXCR4 expression and breast
cancer prognosis is illustrated in Figure 3. Six studies
(including a total of 732 patients) that demonstrated the
association of CXCR4 and the 5-year OS rate were ob-
tained from the published information, and six studies
(including a total of 635 patients) containing information
on the correlation between CXCR4 and the 5-year DFS
rate were obtained from the published articles. CXCR4
overexpression was statistically associated with a poor 5-
year OS rate (Figure 3a, RR = 0.77, 95% CI = 0.70–0.86,
P = 0.554 and I2 = 0 fixed-effect). The 5-year OS rate was
0.77-fold lower in CXCR4-positive patients. Furthermore,
a similar difference was also observed in the 5-year DFS
rate (Figure 3b, RR = 0.70, 95% CI = 0.59–0.83, P = 0.329
and I2 = 13.4 fixed-effect).
Publication bias
Begg’s and Egger’s tests indicated that there was no evi-
dence of significant publication bias after assessing the
funnel plot (Figures 4 and 5) for the studies included in
our meta-analysis.
Discussion
Information about the prognostic and predictive value of
CXCR4 in breast cancer is limited. To our knowledge,
this present meta-analysis is the first study to systematic-
ally evaluate the association between chemokine receptor
CXCR4 and clinicopathological features and prognostic
factors in breast cancer. In our study, a combined analysis
of 13 clinical studies, which detected the CXCR4 antigen
in whole tissue sections, revealed a poor prognostic out-
come in patients expressing high levels of CXCR4. The re-
sults indicate that CXCR4 expression is significantly
associated with lymph node status, distant metastasis and
5-year OS and DFS rates. When compared with nuclear
expression, the expression of CXCR4 in the membrane
and cytoplasm could be more significant for prognosis.
What makes CXCR4 account for the poor prognosis
in breast cancer? On the one hand, CXCR4 is most com-
monly found in malignant cells from different types of
cancer. At least 23 different cancers, including breast can-
cer, express this receptor [23]. Interestingly, Anja et al. re-
ported that CXCR4 was present at a low level or absent in
normal breast tissue but was highly expressed both in pri-
mary and metastatic breast tumors [24]. Hypoxia, vascular
endothelial growth factor (VEGF), transcription factor nu-
clear factor-κB (NF-κB) and estrogen have been shown to
upregulate CXCR4 expression in the tumor microenviron-
ment, leading to cancer cell proliferation, resistance to
apoptosis and local invasion [25,26]. In our study, we also
found that CXCR4 expression was linked to lymph node
status and distant metastasis. Previous studies have shown
that CXCR4 and its chemokine ligand 12 (CXCL12) are
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Figure 2 The forest plot of RRs was assessed for association between CXCR4 and clinicopathological features such as tumor category
(a), N category (b), distant metastasis (c), ER status (d), PR status (e) and c-erbB-2 status (f).
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signaling in response to CXCL12 mediates actin polymer-
ization and pseudopodia formation and subsequently in-
duces chemotactic and invasive responses [28]. Hence,
CXCR4 and CXCL12 form an important signaling axis be-
tween tumor cells and the tumor microenvironment, with
the interaction influencing the adhesion, migration and
invasion of tumor cells, reflecting the strong association
of CXCR4 with breast cancer metastasis. However, other
studies have indicated that CXCR4 is highly expressed
on cancer stem cells, and its activation maintains a stem
cell population in tamoxifen-resistant breast cancer [29].
Cancer stem cells (CSCs) exhibit stem cell-like character-
istics and gain the ability to regenerate the bulk of tumorFigure 3 The forest plot of RRs for the 5-year OS rate (a) and 5-year Dcells while maintaining their self-renewing potential [30].
Hence, CXCR4+ cells could contribute to the development
of therapeutic resistance and relapse in breast cancer.
Furthermore, the CXCR4/CXCL12 axis could mediate
the chemotaxis of cancer stem cells [31] that are in-
volved in the metastasis of breast cancer stem cells and
cancer cell survival and proliferation [32]. Therefore,
CXCR4 could be a marker for poor prognosis and me-
tastasis of breast cancer.
Some limitations exist in the present meta-analysis. First,
the number of included studies was relatively small. Be-
cause these 3865 patients received different treatments
(neoadjuvant therapy or just surgical resection), we were
unable to assess the potential outliers present in individualSF rate (b) among the included studies.
Figure 4 Begg’s test results of CXCR4 and clinicopathological features such as tumor category (a), N category (b), distant metastasis (c),
ER status (d), PR status (e) and c-erbB-2 status (f).
Zhang et al. BMC Cancer 2014, 14:49 Page 6 of 8
http://www.biomedcentral.com/1471-2407/14/49studies. Second, all the studies were from North America
or Asia. Distinct site differences are believed to exist and
could cause publication bias. Finally, the applied method
for detecting CXCR4 expression and the cutoff values were
different in the included studies, which could cause hetero-
geneity among the studies. We could not perform sub-
group analysis to explore this influence because few studies
offered concrete data.
Conclusions
In conclusion, despite the limitations listed above, the
present study showed a significant correlation between
CXCR4 expression and the 5-year OS and DFS rates in
breast cancer patients. CXCR4 expression was also asso-
ciated with lymph node status and distant metastasis.Figure 5 Begg’s test results of the 5-year OS rate (a) and 5-year DSF rThus, CXCR4 could have prognostic significance for pa-
tients with breast cancer. Recent studies indicated that
small antagonists, such as AMD3100, inhibited the pri-
mary tumor and metastasis in animal models of breast
cancer [33]. Hence, CXCR4 antagonists could have a sig-
nificant therapeutic impact on primary and metastatic
breast cancer by disrupting tumor vasculature in the
microenvironment [34]. Furthermore, inhibiting CXCR4
in tumor cells has the potential to induce growth arrest or
apoptosis and to prevent invasion and metastasis [34].
Hence, in addition to being a prognostic marker, CXCR4
could also be an anti-cancer therapy target. Recent preclin-
ical studies in mouse models of leukemia have provided
proof of concept for the greater benefits of combining
CXCR4 inhibition with conventional chemotherapy relativeate (b).
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the case of breast cancer, a CXCR4 inhibitor could improve
survival and prognosis.
Further studies are required to clarify the role of CXCR4
in predicting organ specificity in breast cancer metastasis;
to explain whether CXCR4 could change in the process
of breast cancer neoadjuvant therapy and whether this
change could be significant for treatment and prognosis;
and to evaluate the application of CXCR4 as a bio-marker
for breast cancer prognosis and target therapy. Further-
more, anti-CXCR4 inhibitors need to be carefully assessed
for possible side effects that could occur during immune
cell trafficking or other biological processes.
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